Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Cytokinetics, Incorporated (CYTK) had Return on Equity of 119.00% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$88.04M |
|
$-784.96M |
|
-- |
|
$88.04M |
|
$700.30M |
|
$-612.26M |
|
$-172.70M |
|
$-784.96M |
|
$-784.96M |
|
$-784.96M |
|
$-784.96M |
|
$-784.96M |
|
$-784.96M |
|
$-612.26M |
|
$-602.13M |
|
120.10M |
|
120.10M |
|
$-6.54 |
|
$-6.54 |
|
| Balance Sheet Financials | |
$916.98M |
|
$79.19M |
|
$507.56M |
|
$1.42B |
|
$202.45M |
|
$1.12B |
|
$1.88B |
|
$2.08B |
|
$-659.62M |
|
$-659.63M |
|
$-659.62M |
|
122.94M |
|
| Cash Flow Statement Financials | |
$-510.01M |
|
$16.67M |
|
$524.46M |
|
$95.23M |
|
$125.63M |
|
$30.40M |
|
$112.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.53 |
|
-- |
|
-- |
|
2.45 |
|
-1.75 |
|
100.00% |
|
-695.44% |
|
-695.44% |
|
-683.94% |
|
-891.60% |
|
-891.60% |
|
$-534.82M |
|
-- |
|
-- |
|
-- |
|
0.06 |
|
-- |
|
4.96 |
|
73.65 |
|
|
Return on Equity |
119.00% |
119.00% |
|
-55.10% |
|
-172.00% |
|
$-5.37 |
|
$-4.45 |
|
$-4.25 |
|